Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Or Neurotransmitter (e.g., Insulin, Human Chorionic Gonadotropin, Intragonadal Regulatory Protein, Mullerian Inhibiting Substance, Inhibin, Epidermal Growth Factor, Nerve Growth Factor, Dopamine, Norepinephrine, Etc.) Patents (Class 530/388.24)
  • ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
    Publication number: 20110200602
    Abstract: The invention provides anti-EGFL7 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 18, 2011
    Applicant: Genentech, Inc.
    Inventors: Weilan Ye, Maike Schmidt, Jo-Anne Hongo, Yan Wu
  • Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
    Patent number: 7994294
    Abstract: The present invention relates to all aspects of a guanine exchange factor (GEF), for example, a Rho-GEF, such as p115 Rho-GEF. A GEF modulates cell signaling pathways, both in in vitro and in vivo, by modulating the activity of a GTPase. By way of illustration, a p115 Rho-GEF, which modulates the activity of a Rho GTPase, is described. However, the present invention relates to other GEFs, especially other Rho-GEFs. The present invention particularly relates to an isolated p115 Rho-GEF polypeptide or fragments of it, a nucleic acid coding for p115 Rho-GEF or fragments of it, and derivatives of the polypeptide and nucleic acid. The invention also relates to methods of using such polypeptides, nucleic acids, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: August 9, 2011
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventor: Matthew J. Hart
  • Human TIMP-1 antibodies
    Patent number: 7993849
    Abstract: Human antibodies that bind to TIMP-1 can be used as reagents to diagnose and treat disorders in which TIMP-1 is elevated, such as liver fibrosis, alcoholic liver disease, cardiac fibrosis, acute coronary syndrome, lupus nephritis, glomerulosclerotic renal disease, benign prostate hypertrophy, colon cancer, lung cancer, and idiopathic pulmonary fibrosis.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: August 9, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Clark Pan, Andreas M. Knorr, Michael Schauer, Claudia Hirth-Dietrich, Sabine Kraft, Barbara Krebs
  • ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF
    Publication number: 20110189190
    Abstract: Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit in a human and for the treatment of various disorders, such as anemia, in a human subject. The antibodies of the invention are also useful as analytical tools, such as in sandwich ELISA.
    Type: Application
    Filed: July 29, 2009
    Publication date: August 4, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Donmienne Doen Mun Leung, Peng Luan, Ying Tang, Derrick Ryan Witcher, Pia Pauliina Yachi
  • High affinity human antibodies to human nerve growth factor
    Patent number: 7988967
    Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: August 2, 2011
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Richard Torres, Marc R Morra, Joel H Martin, Joel C Reinhardt
  • ANTI-PLEIOTROPHIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20110182890
    Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.
    Type: Application
    Filed: January 6, 2011
    Publication date: July 28, 2011
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: J. Yun Tso, Anton Wellstein, Debra Chao
  • Anti-inflammatory dAb
    Patent number: 7981414
    Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein the variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: July 19, 2011
    Assignee: Cephalon Australia Pty Ltd
    Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
  • Monoclonal antibody and use thereof
    Patent number: 7981672
    Abstract: The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.
    Type: Grant
    Filed: September 11, 2007
    Date of Patent: July 19, 2011
    Assignee: Immuno-Biological Laboratories Co., Ltd.
    Inventors: Hiroko Kobayashi, Masahiro Hasegawa, Tsutomu Seito
  • Methods for predicting pregnancy outcome in a subject by hCG assay
    Patent number: 7977104
    Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: July 12, 2011
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
  • ANTI-VEGF ANTIBODIES
    Publication number: 20110159009
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Application
    Filed: March 3, 2011
    Publication date: June 30, 2011
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • Method of measuring PTX3 with high sensitivity
    Patent number: 7955807
    Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 7, 2011
    Assignees: The University of Tokyo, Perseus Proteomics Inc.
    Inventors: Tatsuhiko Kodama, Takao Hamakubo, Koji Maemura, Akira Sugiyama, Hiroko Iwanari, Isao Kohno, Yukio Ito
  • MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES
    Publication number: 20110117086
    Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
    Type: Application
    Filed: October 15, 2010
    Publication date: May 19, 2011
    Applicants: BIORÉALITÉS S.A.S., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: JULIE PANNEQUIN, LAURE BOUDIER, DOMINIQUE JOUBERT, FRÉDÉRIC HOLLANDE
  • ANTI-SWEAT ANTIGEN MONOCLONAL ANTIBODY
    Publication number: 20110117103
    Abstract: [Object of the Invention] To provide an antibody that inhibits histamine releasing activity induced by an antigenic substance contained in sweat. [Means for Attaining the Object] An antibody which can react with a sweat antigen composition and inhibit the histamine releasing activity of the composition on a sweat antigen stimulation-responsive cell.
    Type: Application
    Filed: May 1, 2009
    Publication date: May 19, 2011
    Applicant: HIROSHIMA UNIVERSITY
    Inventors: Michihiro Hide, Toshihiko Tanaka, Kaori Ishii, Hidenori Suzuki
  • TREATMENT OF UVEITIS
    Publication number: 20110110934
    Abstract: The present invention relates generally to the use of antagonists of G-CSF, and/or its receptor (G-CSFR) in the treatment of uveitis. The present invention contemplates, therefore, the inhibition of G-CSF or G-CSFR systemically or locally and/or the down-regulation of expression of a G-CSF or G-CSFR in the treatment of uveitis.
    Type: Application
    Filed: October 8, 2010
    Publication date: May 12, 2011
    Applicant: CSL LIMITED
    Inventors: Ian Peter Wicks, Ian Keith Campbell, Ann Leckie Cornish
  • Polynucleotides encoding polypeptides and methods using same
    Patent number: 7939634
    Abstract: Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: May 10, 2011
    Assignee: Compugen Ltd.
    Inventors: Michal Ayalon-Soffer, Zurit Levine, Osnat Sella-Tavor, Alex Diber, Ronen Shemesh, Amir Toporik, Galit Rotman, Sergey Nemzer, Avi Rosenberg, Dvir Dahary, Assaf Wool, Gad S. Cojocaru, Pinchas Akiva, Sarah Pollock, Kinneret Savitsky, Jeanne Bernstein
  • Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
    Patent number: 7939077
    Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: May 10, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
  • CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY
    Publication number: 20110104152
    Abstract: The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.
    Type: Application
    Filed: October 15, 2010
    Publication date: May 5, 2011
    Inventor: Junichiro SONODA
  • Monoclonal antibodies against ANGPTL3
    Patent number: 7935796
    Abstract: Monoclonal antibodies that specifically bind to ANGPTL3 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL3 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 3, 2011
    Assignee: Lexicon Pharmaceuticals, Inc.
    Inventors: E-Chiang Lee, Gregory Landes, Seokjoo Hong, Urvi Desai, David Powell, Xiao Feng
  • TGF-beta binding antibodies
    Patent number: 7927593
    Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: April 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Bryan Edward Jones, James David Pancook, Scott William Rowlinson
  • Antibody against fibroblast growth factor-23
    Patent number: 7923012
    Abstract: The purpose of the present invention is to provide an antibody against fibroblast growth factor 23.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: April 12, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yuji Yamazaki, Takashi Shimada, Takeyoshi Yamashita
  • Assessment of skeletal growth using measurements of NT-CNP peptides
    Patent number: 7919255
    Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: April 5, 2011
    Assignee: Otago Innovation Limited
    Inventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
  • FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING
    Publication number: 20110076279
    Abstract: Vascular endothelial growth factor (VEGF) overexpression is associated with a variety of conditions involving aberrant angiogenesis. Disclosed herein are fully human antibodies that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling Based on their ability to inhibit VEGF signaling, the antibodies disclosed herein may be used to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 31, 2011
    Applicants: SCHERING CORPORATION, XOMA TECHNOLOGY LTD.
    Inventors: Sumant Ramachandra, Walter Robert Bishop, Linda Masat, Chao Bai Huang
  • Monoclonal antibodies, hybridomas, improved method for determining the protein PTX3 and kit for said determination
    Patent number: 7915004
    Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: March 29, 2011
    Assignee: Farma Development S.r.l.
    Inventors: Alberto Mantovani, Giuseppe Peri
  • ANTIBODIES THAT RECOGNIZE CUTTING EDGE WITHIN THE TGF- BETA ACTIVATION CONTROLLING REGION
    Publication number: 20110071278
    Abstract: It is an object of the present invention to provide antibodies capable of detecting an active TGF-? generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-?) generated as a result of generation of active form of human TGF-?1, human TGF-?2 and human TGF-?3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-?1, and corresponding regions of human TGF-?2 and human TGF-?3.
    Type: Application
    Filed: August 13, 2010
    Publication date: March 24, 2011
    Applicant: RIKEN
    Inventors: Soichi KOJIMA, Naoshi DOHMAE, Wakako KONDO
  • Anti-VEGF antibodies
    Patent number: 7910098
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Grant
    Filed: December 1, 2008
    Date of Patent: March 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • Humanized anti-ghrelin antibodies
    Patent number: 7901679
    Abstract: Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: David Matthew Marquis, Eric Michael Smith, Danise Rogers Subramaniam, Derrick Ryan Witcher
  • Anti-CD19 antibodies
    Patent number: 7902338
    Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: March 8, 2011
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
  • RECOMBINANT PRODUCTION OF AUTHENTIC HUMAN PROTEINS USING HUMAN CELL EXPRESSION SYSTEMS
    Publication number: 20110053221
    Abstract: The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.
    Type: Application
    Filed: March 12, 2009
    Publication date: March 3, 2011
    Inventors: Ridong Chen, Soon Seog Jeong, Hui Feng
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110052595
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: June 30, 2009
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Eisuke MEKADA, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Immunological assay and antibodies for anti-mullerian hormone
    Patent number: 7897350
    Abstract: The present invention discloses compositions and methods to measure an amount of Anti-Mullerian Hormone (AMH) in a sample, including a mammalian sample such as a primate, rodent, equine, or bovine sample. The compositions and methods herein also provide antibodies that bind to epitopes on AMH that are stable to proteolysis of AMH.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: March 1, 2011
    Assignees: Beckman Coulter, Inc., Oxford Brookes University
    Inventors: Nigel Patrick Groome, Mark Cranfield, Axel P. N. Themmen, Gopal V. Savjani, Ketusha Mehta
  • Antibodies to heparin-binding growth factor (HBGF) polypeptides
    Patent number: 7897732
    Abstract: Substantially pure heparin-binding growth factor polypeptides (HBGFs), nucleic acids encoding the HBGFs and antibodies which bind to the HBGFs of the invention are provided. The HBGF polypeptides are useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: March 1, 2011
    Assignee: Childrens Hospital Research Foundation
    Inventors: David R. Brigstock, Paul A. Harding
  • Antibodies that specifically bind SOST peptides
    Patent number: 7893218
    Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: February 22, 2011
    Assignee: Stowers Institute for Medical Research
    Inventors: Robb Krumlauf, Debra Ellies
  • Methods and compositions for administering therapeutic and diagnostic agents
    Patent number: 7892547
    Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: February 22, 2011
    Assignee: Immunomedics, Inc.
    Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
  • Modulation of an innate immune response by altering TRIAL-R signaling
    Patent number: 7892539
    Abstract: Methods and composition are provided for modulating innate immunity by modulating activation of the TRAIL receptor. Signaling through the TRAIL-R inhibits the responsiveness of cells including dendritic cells, macrophages, and the like. The activity of these cells is increased or decreased by the administration of agents that inhibit or activate TRAIL-R signaling. Innate immunity includes the production of cytokines that act on the immune system.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: February 22, 2011
    Assignee: The Regents of the University of California
    Inventors: Astar Winoto, Gretchen Elizabeth Diehl, Herman Heng Yue
  • Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
    Publication number: 20110038864
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: September 28, 2010
    Publication date: February 17, 2011
    Applicant: Facet Biotech Corporation
    Inventors: Vinay BHASKAR, Agustin De La Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Human Anti-NGF Neutralizing Antibodies as Selective NGF Pathway Inhibitors
    Publication number: 20110040076
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: Kenneth D. Wild, JR., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Antagonist antibodies against GDF-8
    Patent number: 7888486
    Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF-8), in particular mouse and humanized antibodies, and antibody fragments, including those that inhibit GDF-8 activity and signaling in vitro and/or in vivo. The disclosure also provides methods for diagnosing, treating, ameliorating, preventing, prognosing, or monitoring degenerative orders of muscle, bone, and insulin metabolism, etc., in particular amyotrophic lateral sclerosis (ALS). In addition, the disclosure provides pharmaceutical compositions for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.
    Type: Grant
    Filed: August 14, 2006
    Date of Patent: February 15, 2011
    Assignee: Wyeth LLC
    Inventors: Frank S. Walsh, Margaret M. Zaleska, David S. Howland, Lioudmila Tchistiakova, Riyez Karim, Pamela Kelley, William Kelley, legal representative, Xiang-Yang Tan, Seung Poon Kwak, Menelas N. Pangalos
  • Anti-pleiotrophin antibodies and methods of use thereof
    Patent number: 7888485
    Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: February 15, 2011
    Assignee: Georgetown University
    Inventors: J. Yun Tso, Anton Wellstein, Debra Chao
  • Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
    Patent number: 7884071
    Abstract: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of an aqueous solution of an inorganic or acetic acid salt for producing a pharmaceutical administration form which releases peptides in a continuous manner over a long period of time.
    Type: Grant
    Filed: September 26, 2003
    Date of Patent: February 8, 2011
    Assignee: Zentaris GmbH
    Inventors: Horst Bauer, Thomas Reissmann, Peter Romeis, Berthold Roessler
  • Anti FGF23 antibody and a pharmaceutical composition comprising the same
    Patent number: 7883705
    Abstract: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).
    Type: Grant
    Filed: February 13, 2008
    Date of Patent: February 8, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yuji Yamazaki, Itaru Urakawa, Hitoshi Yoshida, Yukiko Aono, Takeyoshi Yamashita, Takashi Shimada, Hisashi Hasegawa
  • Sclerostin-binding antibodies
    Patent number: 7872106
    Abstract: Compositions and methods relating to epitopes of sclerostin protein, and sclerostin binding agents, such as antibodies capable of binding to sclerostin, are provided.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: January 18, 2011
    Assignees: Amgen Inc., UCB Pharma S.A.
    Inventors: Christopher J. Paszty, Martyn K. Robinson, Kevin Graham, Alistair J. Henry, Kelly S. Warmington, John Latham, Hsieng S. Lu, Alastair Lawson, Andy Popplewell, Wenyan Shen, David G. Winkler, Aaron G. Winters
  • Antibodies that bind to a portion of the VWC domain of connective tissue growth factor
    Patent number: 7871617
    Abstract: The present invention relates to antibodies that bind to a portion of the Von Willebrand's factor (VWC) domain of connective tissue growth factor (CTGF). The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: January 18, 2011
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Hyperglycosylated hCG (invasive trophoblast antigen) in differential diagnosis of malignant or invasive trophoblastic disease
    Patent number: 7871762
    Abstract: The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.
    Type: Grant
    Filed: July 9, 2003
    Date of Patent: January 18, 2011
    Assignee: STC.UNM
    Inventor: Laurence A. Cole
  • MONOCLONAL ANTIBODIES AGAINST ANGPTL4
    Publication number: 20110008359
    Abstract: Monoclonal antibodies that specifically bind to ANGPTL4 are provided. Monoclonal antibodies that neutralize at least one activity of ANGPTL4 are provided. Methods of treating a disorder of lipid metabolism using neutralizing monoclonal antibodies are provided.
    Type: Application
    Filed: December 4, 2009
    Publication date: January 13, 2011
    Applicant: LEXICON PHARMACEUTICALS, INC.
    Inventors: E-Chiang LEE, Gregory M. LANDES, Kyu CHUNG, Ling CHEN, Urvi DESAI, David Reed POWELL, Seokjoo HONG
  • Monoclonal antibodies against osteopontin
    Patent number: 7867725
    Abstract: The present invention relates to reagents and methods for the detection of osteopontin fragments and distinguishing them from each other and from the full-length osteopontin protein. The present invention also relates to assays for the determination of the presence of osteopontin fragments in samples obtained from subjects and, further, the correlation of osteopontin fragment levels fragment levels with disease detection, progression and prognosis.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 11, 2011
    Assignees: Maine Medical Center, University of Maine System Board
    Inventors: Lucy Liaw, Ah-Kau Ng
  • Use of TGF-? antagonists to limit nephrotoxicity of immunosuppressive agents
    Patent number: 7867496
    Abstract: The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-? such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-? antagonist, e.g., an anti-TGF-? antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-? antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: January 11, 2011
    Assignees: Genzyme Corporation, The MCW Research Foundation, Inc., National Institutes of Health
    Inventors: Ashwani K. Khanna, Steven Ledbetter
  • POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
    Publication number: 20100331251
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: March 23, 2010
    Publication date: December 30, 2010
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 7851601
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: December 14, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • Antibodies against human parathyroid hormone related protein
    Patent number: 7842790
    Abstract: Disclosed are an antibody against human para-thyroid-hormone-related protein, a DNA coding for the antibody, a recombinant vector containing the DNA, a transformant transformed with the recombinant vector, a method for preparation of the antibody, and uses of the antibody.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 30, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koh Sato, Yuji Wakahara, Naohiro Yabuta
  • USE OF ESTROGEN AND ANDROGEN BINDING PROTEINS IN METHODS AND COMPOSITIONS FOR TREATING GYNAECOLOGICAL CANCERS
    Publication number: 20100291086
    Abstract: The present invention provides a polypeptide comprising an estrogen or androgen binding region, the binding region capable of binding to an estrogen or androgen at a sufficient affinity or avidity such that upon administration of the polypeptide to a mammalian subject the level of biologically available estrogen or androgen is decreased. The invention also provides for the treatment or prevention of cancers such as ovarian cancer, breast cancer and endometrial cancer using the polypeptides.
    Type: Application
    Filed: September 10, 2008
    Publication date: November 18, 2010
    Inventors: Christopher Hovens, Niall Corcoran, Anthony Costello